Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Loses Neuroscience Chief To Johnson & Johnson

Executive Summary

Eli Lilly & Co. continues to search for a new head of neurology research as its diagnostic drug Amyvid (florbetapir F 18 injection) nears its user fee goal date.
Advertisement

Related Content

Amyvid Training Issues Lead To Complete Response Letter, Could Force More Trials
Amyvid Approval Delay Seems Likely; Questions On Utility Of Training, Plaque Detection Itself Remain
Can Amyvid Be An Important Alzheimer's Product Without An Alzheimer's Indication?
Amyvid Approval Delay Seems Likely; Questions On Utility Of Training, Plaque Detection Itself Remain
Lilly Continues To Bet On Alzheimer's With Avid Acquisition

Topics

Advertisement
UsernamePublicRestriction

Register

PS053213

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel